HP
HealthInvest Partners Portfolio holdings
AUM $234M
1-Year Return
10.88%
This Quarter Return
+18.41%
1 Year Return
+10.88%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$164M
AUM Growth
+$36.6M
(+29%)
Cap. Flow
+$24M
Cap. Flow
% of AUM
14.58%
Top 10 Holdings %
Top 10 Hldgs %
53.05%
Holding
50
New
5
Increased
29
Reduced
6
Closed
6
Top Buys
| 1 |
Merck
MRK
|
+$8.98M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$4.26M |
| 3 |
Eli Lilly
LLY
|
+$3.87M |
| 4 |
Option Care Health
OPCH
|
+$3.21M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$3.09M |
Top Sells
| 1 |
Centene
CNC
|
+$4.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$4.52M |
| 3 |
Cencora
COR
|
+$4.5M |
| 4 |
Cigna
CI
|
+$4.49M |
| 5 |
Gilead Sciences
GILD
|
+$3.44M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IQVIA
IQV
$31.7B
| $2.54M | 1.55% |
10,058
-282
| -3% | -$71.3K |
|
27
Edwards Lifesciences
EW
$44B
| $2.37M | 1.44% |
24,775
+3,960
| +19% | +$378K |
|
|
SWAV
28
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $1.55M | 0.94% |
4,751
+1,221
| +35% | +$398K |
|
29
Corbus Pharmaceuticals
CRBP
$125M
| $1.49M | 0.91% |
+38,000
| New | +$1.49M |
|
30
Cabaletta Bio
CABA
$187M
| $1.32M | 0.8% |
77,540
+56,540
| +269% | +$965K |
|
31
Arcellx
ACLX
$4.27B
| $1.22M | 0.74% |
17,496
+6,096
| +53% | +$424K |
|
32
Krystal Biotech
KRYS
$4.46B
| $1.18M | 0.72% |
6,624
| – | – |
|
33
BridgeBio Pharma
BBIO
$9.85B
| $1.17M | 0.71% |
37,841
+13,856
| +58% | +$428K |
|
34
Exact Sciences
EXAS
$10B
| $1.11M | 0.68% |
16,120
+3,963
| +33% | +$274K |
|
35
Merus
MRUS
$5.13B
| $1.1M | 0.67% |
24,325
| – | – |
|
36
Inspire Medical Systems
INSP
$2.39B
| $1.03M | 0.63% |
4,782
+1,553
| +48% | +$334K |
|
37
Cytokinetics
CYTK
$6.01B
| $982K | 0.6% |
14,000
+2,267
| +19% | +$159K |
|
38
Madrigal Pharmaceuticals
MDGL
$9.53B
| $945K | 0.58% |
3,539
+1,008
| +40% | +$269K |
|
39
MacroGenics
MGNX
$96.7M
| $726K | 0.44% |
+49,307
| New | +$726K |
|
40
Akero Therapeutics
AKRO
$3.42B
| $617K | 0.38% |
24,432
+9,000
| +58% | +$227K |
|
|
AUTL
41
Autolus Therapeutics
AUTL
$349M
| $615K | 0.37% |
96,345
| – | – |
|
42
NewAmsterdam Pharma
NAMS
$2.75B
| $530K | 0.32% |
+22,394
| New | +$530K |
|
|
MORF
43
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $526K | 0.32% |
14,952
| – | – |
|
44
Mersana Therapeutics
MRSN
$36.8M
| $448K | 0.27% |
+4,000
| New | +$448K |
|
|
45
Bristol-Myers Squibb
BMY
$94.1B
| – | – |
-88,000
| Closed | -$4.52M |
|
|
46
Cigna
CI
$78.5B
| – | – |
-15,000
| Closed | -$4.49M |
|
|
47
Centene
CNC
$15.8B
| – | – |
-62,000
| Closed | -$4.6M |
|
48
Pfizer
PFE
$136B
| – | – |
-42,820
| Closed | -$1.23M |
|
49
Prothena Corp
PRTA
$444M
| – | – |
-8,342
| Closed | -$303K |
|
|
AMAM
50
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| – | – |
-57,847
| Closed | -$824K |
|